Pall expands line of proteomics technologies

Pall Corporation has launched a comprehensive line of chromatography sorbents that greatly simplify protein separation and purification for biotechnology drug discovery, development and production.

The integration of this broad range of chromatography media with Pall 's extensive portfolio of membranes, protein purification technologies and services establishes Pall Life Sciences as a single-source provider of the full spectrum of scaleable filtration and separation products for total process solutions in the biopharmaceutical industry.

Additionally, Pall has opened its first two process proteomics service centres, where researchers and manufacturers can access technology to rapidly develop multi-step chromatographic purification schemes, using just small quantities of protein samples. Pall Process Proteomics services can help reduce protein purification cycle time from several months to a matter of days, significantly accelerating the time-to-market of new drug therapies.

Pall recently acquired the BioSepra Process division and its line of sorbents, two of which, MEP and MBI HyperCel, are novel scaleable alternatives to Protein A-based sorbents for antibody production and can reduce processing costs by up to one third. Both are currently being used as part of the production process for ten human therapeutics in various stages of clinical trial.